Expert Perspectives: Immuno Gene & Cell Therapy for the Treatment of Solid Tumors
Hosted by Genenta Science (NASDAQ: GNTA)
Moderated by Brad Loncar
Thursday, April 28, 2022
8:00 AM EDT / 2:00 PM CET
|
In this fireside chat, Genenta is delighted to bring together renowned neuro-oncologist David Reardon, MD (Harvard Medical School, Dana-Farber Cancer Institute) and Professor Luigi Naldini, MD, PhD (San Raffaele Telethon Institute for Gene Therapy), considered by many as the “father” of lentiviral gene therapy to discuss the potential application of immuno gene & cell therapy as a potential treatment for glioblastoma and other solid tumors. Genenta's Temferon™, a lentivirus based hematopoietic stem progenitor cell immuno gene & cell therapy enabling controlled and targeted interferon-α expression within cancers, will be discussed as a potential treatment solution for glioblastoma patients.
Brad Loncar (CEO of Loncar Investments) will serve as the fireside chat moderator and Carlo Russo, MD (Genenta CMO & Head of Development) will also participate in the discussion.
A live question and answer session will follow.
|
|
Registration information
You are required to register in advance for the webcast. For those who are unable to listen at this time, a replay of the call will be available by clicking here.
|
|
|
|
David A. Reardon, MD
David A. Reardon, MD, is a Professor of Medicine at Harvard Medical School and currently serves as Clinical Director of the Center for Neuro-Oncology at the Dana-Farber Cancer Institute.
He previously served as the Associate Deputy Director of the Preston Robert Tisch Brain Tumor Center at Duke University Medical Center for eleven years. He completed his residency at John Hopkins Hospital in Maryland, USA and was awarded a fellowship at the University of Michigan. Dr. Reardon is an active researcher with special interests in the design and implementation of clinical trials for neuro-oncology and the preclinical evaluation of promising therapeutics for central nervous system tumors.
His work includes using innovative clinical therapeutic agents to improve outcomes for patients with brain and spinal tumors, with particular focus on immunotherapeutics. He has also led investigations of molecular-targeting agents, anti-angiogenic reagents, cytotoxins and other biologically-based therapies.
Dr. Reardon has published over 290 peer-reviewed manuscripts. He received the R. Wayne Rundles Award for Excellence in Cancer Research as well as the Award for Excellence in Adult Clinical Research by the Society for Neuro-Oncology in 2015 and 2016. He also served as the tenth president of the Society for Neuro-Oncology from 2013-2015.
|
|
Prof. Luigi Naldini, MD, PhD
Luigi Naldini, MD, PhD is a renowned scientist and academic, and during the last 25 years has pioneered the development and applications of lentiviral vectors for gene therapy. Naldini is Professor of Cell and Tissue Biology and Cell and Gene Therapy at the Vita-Salute San Raffaele University, Milan, Italy, and Director of the San Raffaele-Telethon Institute for Gene Therapy and the Division of Regenerative Medicine, Stem Cells & Gene Therapy at the San Rafaele Scientific Institute. Luigi is also a co-founder of Genenta and serves as Chair of its scientific advisory board.
He has previously served as President of the European Society of Gene and Cell Therapy and a member of the Board of Directors and Advisory Council of the American Society of Gene and Cell Therapy. Luigi is also a scientific advisor on EMEA and WHO committees for the evaluation of novel gene transfer medicines and has authored more than 250 scientific publications. He won numerous awards including the Outstanding Achievement Award from the American Society of Gene and Cell Therapy (ASGCT) in 2014 and from ESGCT in 2015, the Beutler Prize from the American Society of Hematology (ASH) in 2017 and in 2019 the Jeantet-Collen Prize for Translational Medicine.
|
|
Brad Loncar
Brad Loncar is a biotechnology industry investor and founder and CEO of Loncar Investments. He is the creator of two Nasdaq-listed biotech focused exchange-traded funds. Brad previously worked in the financial services industry at Franklin Templeton Investments where he was a member of the Management Training Program, and was appointed to serve in a Senior Advisor role at the U.S. Department of the Treasury. He writes biotechnology commentary at www.LoncarBlog.com, Nasdaq.com and contributes opinion pieces to Endpoints News. Brad is a strategic advisor to Genenta.
|
|
|
|
|
250 West 55th Street, Suite 3401
New York, NY 10019
|
|
Copyright © 2022 LifeSci Advisors, LLC, All rights reserved.
This message contains confidential and proprietary information and is intended only for the individual named. If you are not the named addressee you should not disseminate, distribute or copy this e-mail. Please notify the sender immediately by e-mail if you have received this email by mistake and delete this email from your system. All market prices, data and other information contained in this email are not warranted as to completeness or accuracy and are subject to change without notice. Any comments or statements made herein do not necessarily reflect the views of LifeSci Advisors, LLC, its affiliates, subsidiaries or agents. The message is not intended as an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Before opening any attachments please check them for viruses and defects.
|
|
|
|
|
|
|
